Clinical Takeaway
In this randomized controlled trial of healthy males, CBD at both low (30 mg) and high (700 mg) single doses showed no direct effect on cortical excitability compared to placebo, suggesting CBD may not have meaningful intrinsic anti-epileptic properties on its own. These findings support the hypothesis that CBD’s clinical benefit in seizure disorders like Dravet syndrome and Lennox-Gastaut syndrome is largely driven by its pharmacokinetic interaction with clobazam rather than direct brain activity. Clinicians should interpret this as reinforcing the importance of combination therapy context when evaluating CBD’s role in epilepsy management.
#10 Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.
Citation: Gorbenko Andriy A et al.. Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.. Clinical pharmacology and therapeutics. 2026. PMID: 40836528.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This study challenges prevailing assumptions about CBD’s mechanism of action by demonstrating the absence of direct effects on cortical excitability, suggesting that its clinical efficacy in seizure disorders may depend primarily on pharmacokinetic interactions with co-administered antiepileptic drugs rather than intrinsic anticonvulsant properties. Understanding this distinction is critical for optimizing dosing strategies, predicting drug interactions, and identifying patient populations most likely to benefit from CBD therapy. These findings necessitate reevaluation of how CBD is positioned as monotherapy versus adjunctive treatment and clarify the neurobiological basis for its approved indications.
Abstract: Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD. A randomized, double-blind, placebo-controlled, 3-way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed-effects model. CBD did not have significant effects on single pulse and paired pulse TMS-EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS-EEG at 3 hours post-dose for 30 mg CBD, and at 3 and 5 hours post-dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti-epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.
🧠 This well-designed crossover trial provides useful mechanistic clarity by demonstrating that CBD’s anti-seizure efficacy in approved indications like Dravet syndrome likely operates through drug-drug interactions rather than direct effects on cortical excitability, a finding that challenges some prevailing assumptions about how CBD works. The study’s rigorous methodology strengthens confidence in its negative findings, though clinicians should recognize that absence of direct cortical effects does not diminish CBD’s clinical utility in these specific seizure disorders where pharmacokinetic interactions with clobazam appear to be the operative mechanism. This distinction has practical implications: it suggests CBD’s antiepileptic value may be context-dependent and most robust when combined with specific ASMs, rather than representing a broadly generalizable anti-seizure property, and reinforces the importance of understanding patient-specific medication profiles rather than attributing efficacy to isolated pharmacodynamic actions. For practitioners managing Dravet or Lennox-Gastaut patients, this evidence supports continuing CBD in appropriate combinations